By Steve Scherer and Melissa Ritti ( September 10, 2026, 21:19 GMT | Insight) -- Tulip Licensing launched an imaging-technology licensing program with Canon, Sony, Huawei and OPPO. SB Energy revised its trademark royalty arrangement with SoftBank ahead of its IPO. Roche licensed worldwide rights to Simcere Zaiming’s trispecific antibody in a potential $1.53 billion deal, while Cipla, Leios and Biocytogen announced regional development and commercialization licenses, including agreements involving Chinese-origin assets. Ascendis and BioMarin resolved global patent-related disputes through a royalty-bearing Yuviwel license, and CreeLED resolved a patent suit with LitezAll with a limited license.Roche’s potential $1.53 billion license for Simcere Zaiming’s trispecific antibody and Ascendis Pharma’s royalty-bearing settlement with BioMarin led pharmaceutical licensing and patent-settlement activity spanning oncology, aesthetics and neuroscience. Beyond drug-licensing deals, Tulip Licensing launched an imaging-technology licensing program drawing on portfolios from Canon, Sony, Huawei and OPPO; Universal Music Group partnered with ElevenLabs on a planned platform for licensed AI music remixes; and SB Energy disclosed a revised SoftBank trademark royalty as it prepares for an IPO....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.